[Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome].

AIM: Analysis of the effectiveness of therapy for non-alcoholic fatty liver disease (NAFLD) with severe asthenic syndrome. MATERIALS AND METHODS: In the period from 2017 to 2019, on the basis of the gastroenterology center of the Vishnevsky 3-rd Central Military Clinical Hospital, 247 patients with NAFLD, including those at the stage of steatohepatitis, and severe asthenic syndrome were examined and treated. The main group included 124 patients, the control group 123 patients. All patients underwent complex laboratory and instrumental diagnostics and neuropsychological research using the subjective asthenia assessment scale (MFI-20). In both groups, domestic drugs were included in the therapy regimen: from the 1st to the 10th day, Heptrong solution 3 ml intramuscularly in the morning; from the 1st to the 60th day UDCA 250 mg orally, 3 capsules at bedtime, Omega-3 forte 1000 mg, 2 capsules in the morning with meals. In group I patients received additionally from the 1st to the 10th day intravenous drip Cytoflavin 10 ml + 0.9% NaCl solution 200 ml; pentoxifylline solution 5 ml + 0.9% NaCl solution 200 ml. Then, from the 11th to the 60th day, Cytoflavin inside, 2 tablets 2 times a day. Pentoxifylline inside 400 mg 1 tablet 3 times a day. All patients underwent neuropsychological examination using the subjective asthenia rating scale (MFI-20). RESULTS: The effectiveness of treatment in patients of both groups was assessed by clinical, laboratory data and neuropsychological studies. In the main group, a significant reduction in asthenic syndrome was achieved against the background of diagnosed NAFLD compared with the control group. CONCLUSION: The early inclusion of patients with NAFLD and severe asthenic syndrome in the treatment regimen, in addition to the basic therapy of Cytoflavin, achieved a significantly high therapeutic effect in the form of normalization of the main clinical, laboratory and instrumental parameters, as well as a significant reduction in the manifestations of asthenia.

[The psychophysiological features of nonepileptic paroxysmal disorders].

22 patients with panic disorder without agoraphobia, 19 patients with paroxysmal atrial fibrillation and 43 healthy control subjects with use clinic technique, psychometric, neuropsychological, neurophysiological methods (quantitative EEG and auditory event-related potentials P300) were examined. Patients with panic disorder was differed from patients with paroxysmal atrial fibrillation by higher level of anxiety and greater degree cognitive functions disturbances. In comparison with healthy control subjects at panic disorders increased of P300 peak amplitude and the spectral power of EEG beta and theta bands in the right hemisphere was observed, at paroxysmal atrial fibrillation--decreased of P300 peak amplitude and the spectral power of EEG beta band in the both hemispheres. Obtained data may indicate various origin mechanisms of paroxysmal states or neurotic condition (panic disorder) and psychosomatic (paroxysmal atrial fibrillation).

[Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome]. / Klinicheskaia éffektivnost' neirometabolicheskoi terapii dissomnicheskikh rasstroistv pri astenicheskom sindrome.

AIM: To analyze the efficacy of cytoflavin in the complex treatment of sleep disorders in asthenic syndrome. MATERIAL AND METHODS: One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied. The patients were divided into three groups depending on the type of therapy: the first group received intravenous infusions of cytoflavin for 10 days; the second group, in addition to cytoflavin, received per os melatonin (3 mg or 5 mg) at bedtime; the third group in addition to cytoflavin received per os zopiclone (7.5 mg) at bedtime. RESULTS: On the 14th day of the study, a decrease in severity or complete relief of asthenia manifestations (according to the SHAS scale) and, accordingly, improvement or normalization of sleep in 97% of patients was found. At the same time, during polysomnographic study, the data obtained are characteristic for improving the quality of sleep phases mainly in the first and second groups of patients and, to a lesser extent, in the third group. CONCLUSION: Cytoflavin effectively suppresses the main manifestations of asthenic syndrome, including sleep disorders.

[Psychophysiological characteristics of panic disorder and generalized anxiety disorder].

We studied 34 patients with panic disorder, 32 patients with generalized anxiety disorder and 29 healthy controls using clinical-neurological, psychometric, neuropsychological and neurophysiological (auditory event-related potentials) methods. Patients were characterized by pronounced autonomic dysfunctions, a higher level of anxiety and depression as well as cognitive function disturbances in the form of impairment of short-term memory and directed attention in comparison with healthy controls. Patients with generalized anxiety disorder differed from patients with panic disorder by the higher level of anxiety, greater degree of depression and more expressed disturbances of short-term memory and directed attention. Compared to controls, patients with generalized anxiety disorder had lower P300 amplitudes while the latter was higher in patients with panic disorders. It is concluded that recording of event-related potentials may be used as an additional method of differential diagnosis of these types of anxiety disorders.